8-K: Moleculin Biotech Secures Up to $6.5 Million Through At-The-Market Equity Offering

Moleculin Biotech, Inc. has entered into an At The Market Offering Agreement with Roth Capital Partners, LLC to sell up to $6.5 million of its common stock for working capital and general corporate purposes.

Summary

• Moleculin Biotech, Inc. (the Company) signed an At The Market Offering Agreement (ATM Agreement) with Roth Capital Partners, LLC on July 11, 2025.
• The ATM Agreement allows the Company to sell shares of its common stock with an aggregate sales price of up to $6,500,000.
• Sales will be conducted through Roth Capital as a sales agent and/or principal, utilizing at-the-market offerings or privately negotiated transactions.
• The net proceeds from the sale of shares are intended for working capital and general corporate purposes.
• The offering is being made under the Company's effective shelf registration statement on Form S-3 (File No. 333-280064), which became effective on July 1, 2024.
• The $6,500,000 offering is included in the $200,000,000 of securities authorized under the Company's base prospectus.
• Roth Capital will receive a placement fee of 3.0% of the gross sales price of shares sold.
• The Company will reimburse Roth Capital for counsel fees up to $50,000 upon execution of the agreement, and periodic due diligence fees up to $5,000 per period.
• The Company is not obligated to make any sales, and actual sales will depend on market conditions and the Company's capital needs.
• The agreement can be suspended or terminated by either party, with the Company requiring two business days' notice for termination.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While the offering introduces potential dilution, it secures a crucial and flexible funding mechanism for a biotechnology company, which is essential for its ongoing operations and development. The ability to raise capital is a positive, despite the associated costs and dilution.

Positives

• Secures a flexible and efficient mechanism for raising capital, allowing the Company to access funds as needed based on market conditions.
• The 'at-the-market' nature of the offering provides flexibility in timing and pricing of share sales, potentially minimizing immediate market impact compared to a traditional underwritten offering.
• The capital raised will be used for working capital and general corporate purposes, providing financial flexibility for ongoing operations and strategic initiatives.

Negatives

• The offering involves the sale of new common stock, which will result in dilution for existing shareholders.
• The 3.0% placement fee to Roth Capital Partners, LLC, along with additional reimbursement for counsel and due diligence fees, represents a cost of capital.
• The actual amount of capital raised is uncertain and dependent on market conditions and the Company's discretion, meaning the full $6.5 million may not be realized.

Risks

• Potential dilution of existing shareholders' equity and voting power due to the issuance of new common stock.
• Market conditions may not be favorable for selling shares, potentially limiting the Company's ability to raise the full $6.5 million or forcing sales at lower prices.
• The Company's stock price could be negatively impacted by the perception of future dilution as shares are sold into the market.
• The Company is not obligated to make any sales, meaning there is no guarantee of capital infusion from this agreement.

Future Outlook

The Company intends to use the net proceeds from the sale of shares under the ATM Agreement for working capital and general corporate purposes. The actual amount of capital raised will depend on market conditions and the Company's capital needs, providing flexibility for future operations and strategic initiatives.

Management Comments

• Jonathan P. Foster, Chief Financial Officer, signed the report on behalf of Moleculin Biotech, Inc., indicating management's formal approval and execution of the ATM Agreement.

Industry Context

At-the-market (ATM) offerings are a common and flexible financing tool for biotechnology companies, particularly those in clinical development stages like Moleculin Biotech, which often require continuous capital infusions to fund research, clinical trials, and operational expenses. This mechanism allows companies to raise capital incrementally, reducing the immediate dilutive impact of a large single offering and providing access to funds as specific needs arise or market conditions become favorable, aligning with the typical funding cycles in the biotech industry.

Comparison to Industry Standards

• ATM offerings are a standard financing mechanism for small to mid-cap biotechnology companies, providing a flexible alternative to traditional underwritten offerings.
• The 3.0% placement fee is within the typical range for ATM agreements, which generally vary from 1.0% to 5.0% depending on the size of the offering and the issuer's market capitalization.
• The use of proceeds for 'working capital and general corporate purposes' is standard for such offerings in the biotech sector, reflecting the broad and ongoing funding requirements for drug development.
• The ability to terminate the agreement with short notice (two business days) is a common feature, offering the company control over the timing and volume of sales based on market conditions and capital needs, similar to agreements seen with peers like small-cap biopharmaceutical companies funding clinical trials.

Stakeholder Impact

• Shareholders: Potential for dilution of existing shareholdings as new common stock is issued and sold.
• Company Operations: Provides necessary working capital and funds for general corporate purposes, supporting ongoing research, development, and administrative functions.

Next Steps

• The Company may sell shares from time to time through Roth Capital Partners, LLC, based on its capital needs and market conditions.
• The Company will disclose the number of shares sold, net proceeds, and compensation in its Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, and potentially in Current Reports on Form 8-K if required by SEC policy.

Key Dates

Recommendation

Keywords

At The Market Offering, ATM Agreement, Equity Offering, Capital Raise, Common Stock, Dilution, SEC Filing, Form 8-K, Roth Capital Partners, Moleculin Biotech, MBRX, Shelf Registration, S-3, Working Capital, Corporate Finance